BioMarin to Acquire Alesta Therapeutics for $490 Million

BioMarin Pharmaceutical has announced its agreement to acquire private biotechnology company Alesta Therapeutics for $490 million, aiming to expand its portfolio in rare diseases. The deal is intended to strengthen BioMarin's R&D efforts in gene therapy and neurological disorders. The purchase price may also include additional payments contingent on the achievement of certain milestones. Alesta Therapeutics stands out as a company developing innovative treatment candidates for rare genetic conditions, particularly lysosomal storage diseases. These candidates are expected to create synergies with BioMarin's existing product lineup and play a significant role in the company's long-term growth strategy. The transaction is anticipated to close in the first half of 2025, subject to regulatory approvals. BioMarin's management stated that this acquisition will solidify the company's leadership position in rare diseases and enhance its capacity to offer more comprehensive solutions to patient populations. Additionally, plans are in place to integrate Alesta's preclinical and early clinical stage programs with BioMarin's existing research platforms to accelerate development processes. Financially, the acquisition will be funded using BioMarin's cash reserves and existing credit facilities. The company expects the deal to have a limited impact on profitability in the short term, but to generate new revenue streams in the medium and long term. Investors are closely monitoring whether this move will positively reflect on BioMarin's stock performance. This is not investment advice.